WO2006052691A3 - Pet and magnetic resonance for screening alzheimer's disease therapeutics - Google Patents

Pet and magnetic resonance for screening alzheimer's disease therapeutics Download PDF

Info

Publication number
WO2006052691A3
WO2006052691A3 PCT/US2005/039865 US2005039865W WO2006052691A3 WO 2006052691 A3 WO2006052691 A3 WO 2006052691A3 US 2005039865 W US2005039865 W US 2005039865W WO 2006052691 A3 WO2006052691 A3 WO 2006052691A3
Authority
WO
WIPO (PCT)
Prior art keywords
pet
magnetic resonance
disease therapeutics
screening alzheimer
screening
Prior art date
Application number
PCT/US2005/039865
Other languages
French (fr)
Other versions
WO2006052691A2 (en
Inventor
Julia L Rutkowski
Jack Steven Jacobsen
Orest Hurko
Original Assignee
Wyeth Corp
Julia L Rutkowski
Jack Steven Jacobsen
Orest Hurko
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp, Julia L Rutkowski, Jack Steven Jacobsen, Orest Hurko filed Critical Wyeth Corp
Priority to JP2007540047A priority Critical patent/JP2008519282A/en
Priority to EP05821147A priority patent/EP1807119A2/en
Priority to MX2007005317A priority patent/MX2007005317A/en
Priority to BRPI0517672-7A priority patent/BRPI0517672A/en
Priority to AU2005304931A priority patent/AU2005304931A1/en
Priority to CA002586220A priority patent/CA2586220A1/en
Publication of WO2006052691A2 publication Critical patent/WO2006052691A2/en
Publication of WO2006052691A3 publication Critical patent/WO2006052691A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease

Abstract

Use of animal models of neurodegenerative disorders for establishment of preclinical diagnostic and therapeutic indices, and for screening methods to identify effective preclinical therapies.
PCT/US2005/039865 2004-11-05 2005-11-03 Pet and magnetic resonance for screening alzheimer's disease therapeutics WO2006052691A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2007540047A JP2008519282A (en) 2004-11-05 2005-11-03 Diagnostic imaging modality for screening Alzheimer's disease drugs
EP05821147A EP1807119A2 (en) 2004-11-05 2005-11-03 Pet and magnetic resonance for screening alzheimer's disease therapeutics
MX2007005317A MX2007005317A (en) 2004-11-05 2005-11-03 Imaging modalities for screening alzheimer's disease therapeutics.
BRPI0517672-7A BRPI0517672A (en) 2004-11-05 2005-11-03 Imaging modalities for therapeutic selection of Alzheimer's disease
AU2005304931A AU2005304931A1 (en) 2004-11-05 2005-11-03 Pet and magnetic resonance for screening Alzheimer's disease therapeutics
CA002586220A CA2586220A1 (en) 2004-11-05 2005-11-03 Pet and magnetic resonance for screening alzheimer's disease therapeutics

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62516204P 2004-11-05 2004-11-05
US60/625,162 2004-11-05

Publications (2)

Publication Number Publication Date
WO2006052691A2 WO2006052691A2 (en) 2006-05-18
WO2006052691A3 true WO2006052691A3 (en) 2007-05-10

Family

ID=36129750

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/039865 WO2006052691A2 (en) 2004-11-05 2005-11-03 Pet and magnetic resonance for screening alzheimer's disease therapeutics

Country Status (9)

Country Link
US (1) US20060117397A1 (en)
EP (1) EP1807119A2 (en)
JP (1) JP2008519282A (en)
CN (1) CN101072591A (en)
AU (1) AU2005304931A1 (en)
BR (1) BRPI0517672A (en)
CA (1) CA2586220A1 (en)
MX (1) MX2007005317A (en)
WO (1) WO2006052691A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8257680B1 (en) 2004-02-24 2012-09-04 The General Hospital Corporation Catalytic radiofluorination
US9017724B2 (en) 2004-02-24 2015-04-28 The General Hospital Corporation Catalytic radiofluorination
WO2006124956A1 (en) * 2005-05-17 2006-11-23 Satori Pharmaceuticals, Inc. Compounds useful for treating neurodegenerative disorders
WO2007094830A1 (en) 2005-11-10 2007-08-23 In Silico Biosciences, Inc. Method and apparatus for computer modeling the human brain for predicting drug effects
JP5153114B2 (en) * 2006-10-12 2013-02-27 知宏 千葉 Novel method for detecting Alzheimer's disease
JP5319121B2 (en) * 2007-01-30 2013-10-16 株式会社東芝 Medical support system and medical support device
US20100055036A1 (en) * 2007-03-12 2010-03-04 National Institute of Radiolotgical Sciences Pet visualization of amyloid-associated neuroinflammation in the brain
EP2155259A2 (en) * 2007-05-10 2010-02-24 The Trustees of Columbia University in the City of New York Methods for diagnosing diseases and evaluating treatments therefor using pet
US20090099783A1 (en) * 2007-06-08 2009-04-16 Barry Reisberg Stage Specific Prognostic In Vivo Markers of Brain Aging and Dementia
CL2007002908A1 (en) 2007-10-09 2008-05-30 Univ Concepcion IN VITRO ELECTROCHEMICAL PROCEDURE TO EVALUATE NEUROTOXIC CAPACITY OF STRUCTURES, ACTIVE PRINCIPLES AND / OR INTEREST COMPOUNDS IN LIVE CELLS AND THAT INCLUDES MEASURING AND QUANTIFYING THE ELECTRICAL PARAMETERS IN MEMBRANES EXPOSED TO THESE AGGREGATES
CN102046638B (en) 2008-03-21 2015-06-03 综合医院公司 Compounds and compositions for the detection and treatment of alzheimer's disease and related disorders
EP2265174B1 (en) * 2008-04-04 2018-06-06 The Regents of The University of California Functionalized magnetic nanoparticles and methods of use thereof
US8593141B1 (en) 2009-11-24 2013-11-26 Hypres, Inc. Magnetic resonance system and method employing a digital squid
KR20130114563A (en) * 2010-04-13 2013-10-17 박스터 인터내쇼날 인코포레이티드 Use of ventricular enlargement rate in intravenous immunoglobulin treatment of alzheimer's disease
US8970217B1 (en) 2010-04-14 2015-03-03 Hypres, Inc. System and method for noise reduction in magnetic resonance imaging
DE102012209059A1 (en) 2012-05-30 2013-12-05 Siemens Aktiengesellschaft Method and device for determining a temporal change of a biomarker in a study area
US10203388B2 (en) 2016-01-04 2019-02-12 Toshiba Medical Systems Corporation Magnetic resonance imaging apparatus and magnetic resonance imaging method

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69233774D1 (en) * 1991-01-21 2009-12-10 Elan Pharm Inc Exam and model for Alzheimers disease
ES2155099T3 (en) * 1993-10-27 2001-05-01 Elan Pharm Inc TRANSGENIC ANIMALS THAT HOST APP ALELOS THAT PRESENT A SWEDISH MUTATION.
JPH07132033A (en) * 1993-11-12 1995-05-23 Hoechst Japan Ltd Transgenic animal for alzheimer's disease model
US5877399A (en) * 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
US6717031B2 (en) * 1995-06-07 2004-04-06 Kate Dora Games Method for selecting a transgenic mouse model of alzheimer's disease
US5894078A (en) * 1996-02-26 1999-04-13 Advanced Bioconcept, Inc. Transgenic mouse expressing C-100 app
US5849999A (en) * 1996-10-16 1998-12-15 The Mclean Hospital Corporation Transgenic non-human mice expressing Flag-APP-C100 protein develop alzheimer's disease brain morphology and behavior
US5898094A (en) * 1996-10-21 1999-04-27 University Of South Florida Transgenic mice expressing APPK670N,M671L and a mutant presenilin transgenes
US6284944B1 (en) * 1997-08-29 2001-09-04 Cephalon, Inc, Gene-targeted non-human mammal with a human fad presenilin mutation and generational offspring
US6175057B1 (en) * 1997-10-08 2001-01-16 The Regents Of The University Of California Transgenic mouse model of alzheimer's disease and cerebral amyloid angiopathy
US5846197A (en) * 1998-03-16 1998-12-08 Beth Israel Deaconess Medical Center Compensating for magnetization transfer effects in multislice and three-dimensional MRI blood flow mapping studies
US6664443B1 (en) * 1998-05-01 2003-12-16 Mayo Foundation For Medical Education And Research Pathogenic Tau mutations in transgenic mice
WO2000010614A1 (en) * 1998-08-20 2000-03-02 Regents Of The University Of California METHODS FOR LABELING β-AMYLOID PLAQUES AND NEUROFIBRILLARY TANGLES
US6374130B1 (en) * 1999-04-06 2002-04-16 Eric M. Reiman Methods for tracking the progression of Alzheimer's disease identifying treatment using transgenic mice
US7371920B2 (en) * 2000-06-20 2008-05-13 The Governing Council Of The University Of Toronto Transgenic mouse model of neurodegenerative disorders
US6593516B1 (en) * 2002-10-03 2003-07-15 Rico Corp. Holder for a musical instrument reed
EP1601965A4 (en) * 2003-03-12 2010-11-10 Samaritan Pharmaceuticals Inc Animal model simulating neurologic disease

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2002, VOLMAR C H ET AL: "IMPROVED BEHAVIOR AND INCREASED CEREBRAL BLOOD FLOW BY COX - 2 AND P38 MAPK INHIBITORS IN THE PSAPP ALZHEIMERS DISEASE TRANSGENIC MOUSE MODEL.", XP002417491, Database accession no. PREV200300380895 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; December 2002 (2002-12-01), WEISS C ET AL: "Impaired eyeblink conditioning and decreased hippocampal volume in PDAPP V717F mice.", XP002417492, Database accession no. PREV200300117928 *
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 1992, DETRE J A ET AL: "Perfusion imaging", XP002417553, Database accession no. EMB-1992074052 *
DEDEOGLU ALPASLAN ET AL: "Magnetic resonance spectroscopic analysis of Alzheimer's disease mouse brain that express mutant human APP shows altered neurochemical profile.", BRAIN RESEARCH 25 JUN 2004, vol. 1012, no. 1-2, 25 June 2004 (2004-06-25), pages 60 - 65, XP002417488, ISSN: 0006-8993 *
MAGNETIC RESONANCE IN MEDICINE 1992 UNITED STATES, vol. 23, no. 1, 1992, pages 37 - 45, ISSN: 0740-3194 *
NEUROBIOLOGY OF DISEASE, vol. 11, no. 3, December 2002 (2002-12-01), pages 425 - 433, ISSN: 0969-9961 *
SCHNEIDER L E ET AL: "P2-093: Metabolic mapping of glucose uptake in PSAPP mouse model of AD: sensorimotor hyperarousal correlated with auditory amyloid pathology", NEUROBIOLOGY OF AGING, TARRYTOWN, NY, US, vol. 25, July 2004 (2004-07-01), pages S250, XP004625454, ISSN: 0197-4580 *
SOCIETY FOR NEUROSCIENCE ABSTRACT VIEWER AND ITINERARY PLANNER, vol. 2002, 2002, 32ND ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE; ORLANDO, FLORIDA, USA; NOVEMBER 02-07, 2002, pages ABSTRACT NO. 882.1 *
TOYAMA HIROSHI ET AL: "Absolute quantification of regional cerebral glucose utilization in mice by 18F-FDG small animal PET scanning and 2-14C-DG autoradiography", JOURNAL OF NUCLEAR MEDICINE, vol. 45, no. 8, August 2004 (2004-08-01), pages 1398 - 1405, XP002417487, ISSN: 0161-5505 *
WILLIAMS D S ET AL: "Magnetic resonance imaging of perfusion using spin inversion of arterial water", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 1992 UNITED STATES, vol. 89, no. 1, 1992, pages 212 - 216, XP002417486, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
BRPI0517672A (en) 2008-10-14
CN101072591A (en) 2007-11-14
US20060117397A1 (en) 2006-06-01
AU2005304931A1 (en) 2006-05-18
EP1807119A2 (en) 2007-07-18
WO2006052691A2 (en) 2006-05-18
MX2007005317A (en) 2007-06-11
JP2008519282A (en) 2008-06-05
CA2586220A1 (en) 2006-05-18

Similar Documents

Publication Publication Date Title
WO2006052691A3 (en) Pet and magnetic resonance for screening alzheimer's disease therapeutics
WO2006102370A3 (en) Functional brain mri mapping as a marker in cns diseases and disorders
EA200702095A1 (en) ANTIBODIES DIRECTED AGAINST BETA AMYLOID PEPTIDE, AND METHODS FOR THEIR USE
EP1951892A4 (en) Antibody treatment of alzheimer's and related diseases
WO2009027105A3 (en) Method of providing patient specific immune response in amyloidoses and protein aggregation disorders
WO2005025516A3 (en) Monoclonal antibodies specific for conformational epitopes of prefibrillar aggregates
WO2008156622A8 (en) Humanized antibodies to amyloid beta
WO2008068024A3 (en) Means and methods for isolating and determining novel targets for the treatment of neurodegenerative, neurological or neuropsychiatric disorders and compositions comprising the same
IL177787A0 (en) 1-aminovyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease
WO2008155133A3 (en) Fusion protein comprising a caspase domain and a nuclear hormone receptor binding domain and methods and uses thereof
WO2011072257A3 (en) Amyloid binding agents
IL188165A0 (en) Method for the diagnosis of alzheimer's disease
IL208926A0 (en) Use of epothelone d in treating tau-associated diseases including alzheimer's disease
EP2091566A4 (en) Combination treatments for alzheimer's disease and similar diseases
EP1817050A4 (en) Diagnosis and treatment of alzheimer's disease
EP1744762A4 (en) Transgenic models of alzheimer"s disease and uses thereof in the treatment of a variety of neurodegenerative diseases
WO2008122441A3 (en) Anti-amyloid antibodies and their use in diagnosis and therapy of amyloid diseases
ITRM20040212A1 (en) NON-HUMAN TRANSGENIC ANIMAL AS A MODEL FOR NEURODEGENERATIVE DISEASES AND THEIR EARLY DIAGNOSIS.
WO2004093830A3 (en) Model for neurodegenerative disorders
WO2006091964A3 (en) Regulators of protein misfolding and aggregation and methods of using the same
WO2008006087A3 (en) Antibodies to conformationally trapped proteins
WO2008061209A3 (en) G protein coupled receptors and uses thereof
WO2005117577A3 (en) Model for neurodegenerative disorders
GB2431348B (en) Agents and methods for early diagnosis and monitoring of alzheimer's disease and other neurological disorders
PH12012501882A1 (en) Humanized antibody against amyloid beta

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005821147

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2586220

Country of ref document: CA

Ref document number: 2007540047

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/005317

Country of ref document: MX

Ref document number: 3292/DELNP/2007

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005304931

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200580041699.5

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2005304931

Country of ref document: AU

Date of ref document: 20051103

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005304931

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005821147

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0517672

Country of ref document: BR